1 – 10 of 16
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors
(
- Contribution to journal › Article
-
Mark
Quality of life in a large multinational haemophilia B cohort (The B-Natural study) – Unmet needs remain
(
- Contribution to journal › Article
-
Mark
Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS-IPS study
(
- Contribution to journal › Article
- 2021
-
Mark
Natural history study of factor IX deficiency with focus on treatment and complications (B-Natural)
(
- Contribution to journal › Article
- 2020
-
Mark
Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease : Results from 3WINTERS-IPS, an international and collaborative cross-sectional study
(
- Contribution to journal › Article
- 2017
-
Mark
Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors
(
- Contribution to journal › Article
- 2016
-
Mark
The european hematology association roadmap for european hematology research : A consensus document
(
- Contribution to journal › Article
- 2013
-
Mark
The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.
(
- Contribution to journal › Article
-
Mark
Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study
(
- Contribution to journal › Article
-
Mark
Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A
(
- Contribution to journal › Article